Patents Assigned to Bergenbio AS
  • Anti-AXL Antagonistic Antibodies
    Publication number: 20230406941
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: February 17, 2023
    Publication date: December 21, 2023
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn Hodneland NILSSON, Tone SANDAL
  • Combination Therapy Comprising an AXL Inhibitor
    Publication number: 20230372337
    Abstract: This disclosure relates to a combination therapy for treating patients suffering from a proliferative disease. More particularly, the disclosure relates to combination therapies comprising an AXL inhibitor, an immune checkpoint modulator (ICM), and a chemotherapeutic agent and/or radiotherapy for treating patients suffering from cancer, as well as compositions and methods for treating patients with said combination therapy.
    Type: Application
    Filed: March 23, 2021
    Publication date: November 23, 2023
    Applicant: BERGENBIO ASA
    Inventor: James LORENS
  • Anti-axl antagonistic antibodies
    Patent number: 11732048
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: August 22, 2023
    Assignees: Bergen Teknologioverføring AS, BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Nilsson, Tone Sandal
  • AXL Inhibitors for Antiviral Therapy
    Publication number: 20230250169
    Abstract: This disclosure relates to compostions and methods for preventing and treating a viral infection in a subject. In particular, the present disclosure provides compostions and methods of preventing or treating infection of a subject with a coronavirus such as the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) that causes the disease COVID-19.
    Type: Application
    Filed: April 1, 2021
    Publication date: August 10, 2023
    Applicant: BERGENBIO ASA
    Inventors: James Bradley LORENS, Wendy MAURY
  • Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator
    Publication number: 20230151100
    Abstract: The invention relates to a method of selecting a subject for treatment with a combination of an AXL inhibitor (AXLi) and an immune checkpoint modulator (ICM), the method comprising: identifying subjects having an AXL-related disease characterised by the presence of cells having modified STK11 activity or expression; and, selecting thus identified subjects for treatment. The invention also relates to an AXL inhibitor (AXLi) and an immune checkpoint modulator (ICM) for use in the treatment of an AXL-related disease.
    Type: Application
    Filed: April 23, 2021
    Publication date: May 18, 2023
    Applicants: BERGENBIO ASA, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: James LORENS, David MICKLEM, Huiyu LI, Zhida LIU, John MINNA, Rolf BREKKEN
  • Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus
    Publication number: 20230149397
    Abstract: The present invention concerns an Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
    Type: Application
    Filed: December 16, 2022
    Publication date: May 18, 2023
    Applicant: BERGENBIO ASA
    Inventors: James Bradley LORENS, Gro GAUSDAL
  • Anti-Axl antagonistic antibodies
    Patent number: 11584796
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: February 21, 2023
    Assignees: BERGENBIO ASA, BERGEN TEKNOLOGIOVERFØRING AS
    Inventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Hodneland Nilsson, Tone Sandal
  • Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus
    Patent number: 11534440
    Abstract: An Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: December 27, 2022
    Assignee: BERGENBIO ASA
    Inventors: James Bradley Lorens, Gro Gausdal
  • Anti-Axl Antagonistic Antibodies
    Publication number: 20220195054
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: November 2, 2021
    Publication date: June 23, 2022
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn NILSSON, Tone SANDAL
  • ANTI-AXL ANTIBODIES
    Publication number: 20220185897
    Abstract: Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: October 18, 2021
    Publication date: June 16, 2022
    Applicant: BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
  • Anti-Axl antagonistic antibodies
    Patent number: 11198734
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the AxI protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: December 14, 2021
    Assignees: Bergen Teknologioverføring AS, BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Nilsson, Tone Sandal
  • Anti-Axl antibodies
    Patent number: 11186643
    Abstract: Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: November 30, 2021
    Assignee: BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
  • Serum Biomarkers
    Publication number: 20210215697
    Abstract: The present disclosure relates to the field of cancer biomarkers and treatments, and more particularly to methods of predicting susceptibility to cancer treatments, in particular treatments with Axl inhibitors. Also disclosed are products, such as kits, having utility in performing the disclosed methods.
    Type: Application
    Filed: May 13, 2019
    Publication date: July 15, 2021
    Applicant: BerGenBio ASA
    Inventors: Robert Holt, David Micklem
  • Humanized anti-AXL antibodies
    Patent number: 11059893
    Abstract: The present disclosure relates to humanized anti-Axl antibodies.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: July 13, 2021
    Assignee: BERGENBIO ASA
    Inventors: Patricius Hendrikus Cornelis Van Berkel, David G. Williams
  • Biomarkers for cancer
    Patent number: 11035008
    Abstract: The use of PHGDH as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of PHGDH modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring PHGDH expression and/or activity.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 15, 2021
    Assignee: BerGenBio ASA
    Inventors: Monica Hellesoy, Linn Hodneland Nilsson, David Robert Micklem
  • Anti-Axl Antagonistic Antibodies
    Publication number: 20210171643
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: June 21, 2017
    Publication date: June 10, 2021
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn NILSSON, Tone SANDAL
  • Pharmaceutically Active Compounds
    Publication number: 20210070708
    Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
    Type: Application
    Filed: July 14, 2020
    Publication date: March 11, 2021
    Applicant: BerGenBio ASA
    Inventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
  • Pharmaceutically active compounds
    Patent number: 10766861
    Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: September 8, 2020
    Assignee: BerGenBio ASA
    Inventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
  • COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS
    Publication number: 20200215064
    Abstract: An Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 9, 2020
    Applicant: BerGenBio ASA
    Inventors: James Bradley LORENS, Gro GAUSDAL
  • METHOD
    Publication number: 20200072839
    Abstract: The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity.
    Type: Application
    Filed: May 10, 2019
    Publication date: March 5, 2020
    Applicant: BERGENBIO ASA
    Inventors: Jim Lorens, Crina Tiron